WO2012067482A2 - COMPOSICIÓN FARMACÉUTICA ADAPTADA PARA ADMINISTRARSE ORALMENTE Y PROCESO PARA SU PREPARACIÓN, PARA PREVENCIÓN Y TRATAMIENTO DEL SÍNDROME DE INTESTINO IRRITABLE, A BASE DE UN MODIFICADOR DE LA MOTILIDAD INTESTINAL Y α-D-GALAGTOSIDASA - Google Patents
COMPOSICIÓN FARMACÉUTICA ADAPTADA PARA ADMINISTRARSE ORALMENTE Y PROCESO PARA SU PREPARACIÓN, PARA PREVENCIÓN Y TRATAMIENTO DEL SÍNDROME DE INTESTINO IRRITABLE, A BASE DE UN MODIFICADOR DE LA MOTILIDAD INTESTINAL Y α-D-GALAGTOSIDASA Download PDFInfo
- Publication number
- WO2012067482A2 WO2012067482A2 PCT/MX2011/000139 MX2011000139W WO2012067482A2 WO 2012067482 A2 WO2012067482 A2 WO 2012067482A2 MX 2011000139 W MX2011000139 W MX 2011000139W WO 2012067482 A2 WO2012067482 A2 WO 2012067482A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- composition according
- intestinal motility
- preparing
- modifier
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 61
- 230000008991 intestinal motility Effects 0.000 title claims abstract description 38
- 239000003607 modifier Substances 0.000 title claims abstract description 36
- 102000005840 alpha-Galactosidase Human genes 0.000 title claims abstract description 28
- 108010030291 alpha-Galactosidase Proteins 0.000 title claims abstract description 28
- 208000002551 irritable bowel syndrome Diseases 0.000 title claims abstract description 18
- 230000002265 prevention Effects 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 3
- 239000003826 tablet Substances 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 34
- 238000004519 manufacturing process Methods 0.000 claims description 33
- 229960005345 trimebutine Drugs 0.000 claims description 26
- 239000011230 binding agent Substances 0.000 claims description 19
- LORDFXWUHHSAQU-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid [2-(dimethylamino)-2-phenylbutyl] ester Chemical compound C=1C=CC=CC=1C(CC)(N(C)C)COC(=O)C1=CC(OC)=C(OC)C(OC)=C1 LORDFXWUHHSAQU-UHFFFAOYSA-N 0.000 claims description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 229920002678 cellulose Polymers 0.000 claims description 11
- 239000001913 cellulose Substances 0.000 claims description 11
- 208000028774 intestinal disease Diseases 0.000 claims description 11
- 239000000314 lubricant Substances 0.000 claims description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 239000007884 disintegrant Substances 0.000 claims description 8
- 238000009826 distribution Methods 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 239000000375 suspending agent Substances 0.000 claims description 5
- 239000000454 talc Substances 0.000 claims description 5
- 235000012222 talc Nutrition 0.000 claims description 5
- 229910052623 talc Inorganic materials 0.000 claims description 5
- 238000009736 wetting Methods 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- IKGXLCMLVINENI-QOXGANSBSA-M [Br-].COc1cc(Br)c(C[N+]2(CCOCC[C@@H]3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC Chemical compound [Br-].COc1cc(Br)c(C[N+]2(CCOCC[C@@H]3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC IKGXLCMLVINENI-QOXGANSBSA-M 0.000 claims description 3
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 claims description 3
- 229960003550 alosetron Drugs 0.000 claims description 3
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 claims description 3
- 229960002777 dicycloverine Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001571 loperamide Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- QNPHCSSJLHAKSA-UHFFFAOYSA-N pargeverine Chemical compound C=1C=CC=CC=1C(OCC#C)(C(=O)OCCN(C)C)C1=CC=CC=C1 QNPHCSSJLHAKSA-UHFFFAOYSA-N 0.000 claims description 3
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 claims description 3
- 229960002088 pinaverium bromide Drugs 0.000 claims description 3
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 claims description 3
- 229960002876 tegaserod Drugs 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000003474 anti-emetic effect Effects 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims 3
- 229920002261 Corn starch Polymers 0.000 claims 2
- 239000008120 corn starch Substances 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 229940099112 cornstarch Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 239000008240 homogeneous mixture Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 description 18
- 239000007789 gas Substances 0.000 description 15
- 239000002994 raw material Substances 0.000 description 9
- 206010000060 Abdominal distension Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- FSRLGULMGJGKGI-BTJKTKAUSA-N Trimebutine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=CC=1C(CC)(N(C)C)COC(=O)C1=CC(OC)=C(OC)C(OC)=C1 FSRLGULMGJGKGI-BTJKTKAUSA-N 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 230000009278 visceral effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 3
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 3
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 208000024330 bloating Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 206010016766 flatulence Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 3
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000001294 Nociceptive Pain Diseases 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 235000014571 nuts Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- MNBSXKSWDLYJHN-UHFFFAOYSA-N 2,4,6-trimethylbenzene-1,3,5-triol Chemical compound CC1=C(O)C(C)=C(O)C(C)=C1O MNBSXKSWDLYJHN-UHFFFAOYSA-N 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 235000010523 Cicer arietinum Nutrition 0.000 description 1
- 244000045195 Cicer arietinum Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 240000004322 Lens culinaris Species 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 240000006711 Pistacia vera Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- ZFPDLGDYDUPYEZ-UHFFFAOYSA-N [2-(methylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate Chemical compound C=1C=CC=CC=1C(CC)(NC)COC(=O)C1=CC(OC)=C(OC)C(OC)=C1 ZFPDLGDYDUPYEZ-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 244000193174 agave Species 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000035873 hypermotility Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229950002341 pargeverine Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000020233 pistachio Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000010346 psychosocial stress Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- -1 sucrose disaccharide Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940030049 trimethylphloroglucinol Drugs 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
Definitions
- the present invention relates to a pharmaceutical composition or formulation in the form of a tablet, coated tablet, capsule or powder to be reconstituted for use in irritable bowel syndrome, also known as irritable bowel syndrome, based on a motility modifier. intestinal and enzyme aD-galactosidase.
- Irritable bowel syndrome formerly known as irritable bowel syndrome
- SU is a functional disorder of the intestine, characterized by symptoms of abdominal discomfort or pain that are associated with alterations of bowel habit.
- SU is understood as the result of the interaction of many factors that contribute to the appearance of symptoms in common, rather than to a disease with a specific etiology. It is important to mention that there is no single pathophysiological mechanism that explains the etiology of Sil however, there are at least 3 interrelated factors present in patients who suffer from it, however, in a variable form from individual to individual.
- SU is one of the most frequent health disorders in the world, being more common in women between the ages of 30 and 50, with a prevalence in Latin America between 9 to 18% (Schmulson, Max J. 2008. Limited diagnostic scrutiny may reduce the direct economic impact of irritable bowel syndrome (SU) Rev Med Chile, Vol. 136: 1398-1405).
- the symptomatic pattern in Mexico is SU with constipation; Abdominal distention is a frequent symptom in this disease pattern.
- abdominal distension and gas are reported as very high frequency symptoms.
- Irritable bowel syndrome is a true pathological entity that has a significant impact on those who suffer from it (severity of symptoms, functional impairment, decreased quality of life), in addition to constituting an important economic burden for society and the state, in terms of costs of medical care and work abstention (American Gastroenterological Association. 2002. American Gastroenterological Association position statement: irritable bowel syndrome. Gastroenterology .; Vol. 123, No. 6: 2105-7).
- trimebutine maleate commonly known as trimebutine since 1969
- trimebutine since 1969
- its main effects are the regularization of intestinal motility and elevation of the threshold to pain caused by visceral distention (Román FJ, et al. 1999. Pharmacological properties of trimebutine and N-monodesmethyltrimebutine. J Pharmacol Exp. Ther .; Vol. 289, No. 3: 1391- 1397).
- fragmentation of non-absorbable oligosaccharides found in legumes, fruits and other vegetables, before they reach the colon (where they will be fermented by bacterial flora and gas will be produced) may represent an attractive alternative.
- the administration of ⁇ -D-galactosidase can achieve this effect (Di Stefano M., et al. 2007. The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. Dig Dis Sci. January. Vol. 52, No. 1: 78-83).
- All the aforementioned products can be used in combination with a-D-galactosidase to prepare a pharmaceutical formulation for oral administration to treat, relieve and mitigate intestinal disorders such as irritable bowel syndrome.
- ⁇ -D-galactosidase is produced by several microorganisms, which is used as a medicine, comes from the non-toxic and food-grade fungus Aspergillus niger (http://www.beanogas.com accessed 28 April 2009).
- trimebutine and its salts an intestinal motility regulating agent with analgesic properties and the enzyme ⁇ -D-galactosidase that reduces the production of gas by fermentation of carbohydrates in the colon (and therefore, visceral distention), It is proposed as an effective treatment in the reduction of symptoms in patients with irritable bowel syndrome.
- Trimebutin acts on the plexus of Auerbach (muscular) and MeiSsner (submucosal), it does so on the encephalinergic receptors responsible for the regulation of peristaltic movements. Trimebutine acts in both hypermotility and hypomotility, depresses or stimulates peristalsis and leads to normalization of intestinal transit. Trimebutine also has analgesic (modulates visceral sensitivity), antispasmodic and antiemetic (Delvaux M. & Wingate D. 1997. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J. Int. Med. Res. Vol. 25, No. 5: 225-46).
- ⁇ -D-galactosidase hydrolyzes non-absorbable oligosaccharides in the intestinal tract to prevent them from becoming fermented by the intestinal bacterial flora (gas-producing process); by reducing the production of intestinal gas, it decreases visceral distention and therefore symptoms such as bloating, pain abdominal and flatulence (http://www.beanogas.com accessed April 28, 2009).
- ⁇ -D-galactosidase hydrolyzes three complex carbohydrates: raffinose, stachyose and verbascosa, to transform them into monosaccharides: Glucose, galactose and fructose, and sucrose disaccharide (hydrolysis is instantaneous in normal digestion).
- the enzyme ⁇ -D-galactosidase is not normally produced by humans, so that raffinose, stachyose or verbascosa arrive intact in the colon, where they are fermented by bacterial flora, a chemical reaction that produces hydrogen and methane (gas).
- Legumes Beans, chickpeas, lentils, peas, soybeans, beans. Fruits: orange, banana, kiwi, grapefruit.
- Seeds peanuts, almonds, hazelnut, walnut, pine nut, pistachios.
- Other vegetables Asparagus, broccoli, carrot, cabbage, cucumber, onion, mushrooms, mushrooms, potatoes, peppers, leek (pore).
- WO2001 / 047515 discloses the use of trimebutine itself to prepare a medicine, however, it only focuses on the relief of symptoms of this condition not the condition itself.
- Application MXPA02006376 discloses the use of trimebutine itself to prevent or treat somatic pain and inflammation associated with conditions Gastric, however, is limited to the treatment of symptoms, not the condition or the causes that cause it.
- US 2004/0009234 discloses a pharmaceutical composition and associated treatment to prevent gastrointestinal disorders using only trimebutine without preventing gastrointestinal disorders since it does not combat the origin of such conditions.
- Document MX00PA05010821 A discloses the use of trimebutine for the treatment of constipation, without achieving the desired end result, by not combating the origin of these conditions.
- WO001995001803 discloses the use of trimebutin for the prevention or treatment of gastrointestinal pain and disorders such as indigestion, excess food intake, esophageal reflux, dyspepsia and constipation, however, pain is not prevented.
- gastrointestinal since its origin is not resolved.
- An object of the present invention is to provide a pharmaceutical formulation for oral administration, with application in intestinal disorders based on a modifier of intestinal motility and a-D-galactosidase.
- Another object of the present invention is to provide a pharmaceutical formulation for oral administration with application in intestinal disorders based on a modifier of intestinal motility and ⁇ -D-galactosidase to normalize intestinal transit.
- Still another object of the present invention is to provide a pharmaceutical formulation for oral administration, with application in intestinal disorders to basis of a modifier of intestinal motility and ⁇ -D-galactosidase, effective to achieve an analgesic activity in the treatment of gastrointestinal disorders.
- Another object of the present invention is to provide a pharmaceutical formulation for oral administration, with application in intestinal disorders based on a modifier of intestinal motility and ⁇ -D-galactosidase, effective to achieve an antispasmodic activity.
- a further object of the present invention is to provide a pharmaceutical formulation for oral administration, with application in intestinal disorders based on a modifier of intestinal motility and aD-galactosidase, effective in reducing symptoms related to intestinal gas such as bloating, Pain and flatulence
- the pharmaceutical formulation in the form of a tablet, coated tablet, capsule or powder to reconstitute, to treat irritable bowel syndrome, also known as irritable bowel syndrome, based on a modifier of intestinal motility and the enzyme ⁇ -D- galactosidase, is prepared according to the following procedure:
- the intestinal motility modifier (100-200 mg), the enzyme ⁇ -D-galactosidase, a binding agent (2-10%), a diluent (20-50%), a disintegrant (1-10) are mixed %), a lubricant (0.25 - 5%) and a slider (0.2 - 5%).
- a binder solution is prepared.
- the intestinal motility modifier, the a-D-galactosidase enzyme, a binder, a diluent, a disintegrant, a lubricant and a slider, are screened with a mesh sieve of 450 to 2000 microns in order to disintegrate the lumps.
- the product resulting from the previous step is ground, dried and screened prior to grinding.
- the mixture is compressed to form a tablet or a coated tablet, otherwise (the granulate) capsules are prepared.
- Ugal refers to the enzymatic activity of ⁇ -D-galactosidase, starting from a raw material with lOOOOUgal per gram.
- Procedure of Example 1 Manufacture of trimebutine maleate, in combination with ⁇ -D-galactosidase by wet granulation. Intra-granular enzyme addition
- step 6 Grind the product obtained in step 6 through a mill with a sieve of 0.033 to 0.094 inches and a speed of 500 to 1500 rpm.
- step 8 Pass through a sieve with a mesh opening of 420 to 2,000 microns, the mixture of colloidal-lactose-cellulose silicon dioxide 75:25 obtained in step 8, the talcum powder, the rest of lactose-cellulose 75:25 and magnesium stearate.
- the lactose-cellulose 75:25 obtained in step 9 The mixture of colloidal silicon dioxide — lactose-cellulose 75:25 obtained in step 9.
- step 11 Add the magnesium stearate obtained in step 9 to the mixer and mix with the product for 5 to 10 minutes and 15 to 30 rpm.
- Ugal refers to the enzymatic activity of ⁇ -D-galactosidase, starting from a raw material with 1 OOOUgal per gram.
- step 6 Grind the product obtained in step 6 through a mill with a sieve with a hole of 0.033 to 0.094 inches and an impeller blade speed of 500 to 1500 rpm.
- Lactose-Cellulose 75:25 approximately equal to colloidal silicon dioxide and mix until a homogeneous distribution is obtained.
- step 11 Add the magnesium stearate obtained in step 9 to the mixer and mix with the product for 5 to 10 minutes and 15 to 30 rpm.
- Ugal refers to the enzymatic activity of a-D-galactosidase, starting from a raw material with 5000 Ugal per gram.
- Procedure of Example 3 Manufacture of trimebutine maleate, in combination with ⁇ -D-galactosidase by direct compression.
- step 1 Sift through a sieve with a mesh opening of 420 to 2,000 microns, the mixture of colloidal silicon dioxide-microcrystalline cellulose obtained in step 1.
- step 5 Add the magnesium stearate obtained in step 3 to the mixer and mix with the product for 5 to 10 minutes and 15 to 30 rpm.
- Ugal refers to the enzymatic activity of aD-galactosidase, starting from a raw material with 10,000 Ugal per gram.
- Procedure of Example 4 Manufacture of trimebutine maleate, in combination with ⁇ -D-galactosidase by mixing powders. Powder to reconstitute. 1. Mix an amount of microcrystalline cellulose approximately equal to colloidal silicon dioxide and mix until a homogeneous distribution is obtained.
- step 1 Sift through a sieve with a mesh opening of 420 to 2,000 microns, the mixture of colloidal silicon dioxide-microcrystalline cellulose obtained in step 1.
- the binder is selected from those excipients that impart cohesiveness to the powdered materials, forming granules.
- the diluent is selected from those excipients that have the function of increasing the apparent volume of the powder, and therefore, increase the weight of the tablet and / or the capsule.
- the disintegrant is selected from those excipients which are capable of breaking (disintegration) the tablet and the granules when they come into contact with a liquid.
- the lubricant is selected from those excipients that are capable of reducing friction between the granules and the matrix wall during the process of compression or filling of capsules.
- the slider is selected from those excipients that are capable of providing flow from the hopper granules to the die cavity by reducing interparticle friction.
- the suspending agent is selected from those excipients to increase viscosity and retard sedimentation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013539789A JP2013542986A (ja) | 2010-11-16 | 2011-11-15 | 過敏性腸症候群の予防と治療のための、腸運動調整剤とα−D−ガラクトシダーゼとを含む経口投与用医薬組成物及びその調製方法 |
RU2013127273/15A RU2013127273A (ru) | 2010-11-16 | 2011-11-15 | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, АДАПТИРОВАННАЯ ДЛЯ ОРАЛЬНОГО ВВЕДЕНИЯ, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ ДЛЯ ПРЕДОТВРАЩЕНИЯ И ЛЕЧЕНИЯ СИНДРОМА РАЗДРАЖЕННОГО КИШЕЧНИКА НА ОСНОВЕ МОДИФИКАТОРА МОТОРИКИ КИШЕЧНИКА И ФЕРМЕНТА α-D-ГАЛАКТОЗИДАЗЫ |
CN2011800651365A CN103392000A (zh) | 2010-11-16 | 2011-11-15 | 用于预防和治疗肠易激综合征的、包含肠能动性调节剂和α-D-半乳糖苷酶的口服给药的药物组合物及其制备方法 |
BR112013012102A BR112013012102A2 (pt) | 2010-11-16 | 2011-11-15 | composição farmacêutica adaptada para ser administrada oralmente em forma de comprimido, comprimido revestido, cápsula ou pó para reconstituir, com aplicação em distúrbios intestinais, processo para preparar uma composição farmacêutica e uso de uma composição farmacêutica |
EP11841178.4A EP2641968A4 (en) | 2010-11-16 | 2011-11-15 | ORAL ADMINISTRATIVE PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF REIZDARY SYNDROME WITH AN INNSTIMAL MOBILITY MODEL AND ALPHA-D-GALACTOSIDASE AND METHOD OF PREPARING THEREOF |
KR1020137015555A KR20140037798A (ko) | 2010-11-16 | 2011-11-15 | 장 운동성 조절제 및 α-D-갈락토시다아제를 포함하는, 과민성 장 증후군의 예방 및 치료를 위한, 경구 투여용 약제학적 조성물 및 그의 제조 방법 |
US13/885,629 US20150150953A1 (en) | 2010-11-16 | 2011-11-15 | PHARMACEUTICAL COMPOSITION ADAPTED FOR ORAL ADMINISTRATION AND THE PROCESS FOR ITS PREPARATION, FOR THE PREVENTION AND TREATMENT OF IRRITABLE BOWEL SYNDROME, BASED ON AN INTESTINAL MOTILITY MODIFIER AND a-D-GALACTOSIDASE |
CA2818130A CA2818130A1 (en) | 2010-11-16 | 2011-11-15 | Orally administered pharmaceutical composition and preparation method thereof, for the prevention and treatment of irritable bowel syndrome, comprising an intestinal motility modifier and a-d-galactosidase |
AU2011329917A AU2011329917A1 (en) | 2010-11-16 | 2011-11-15 | Orally administered pharmaceutical composition and preparation method thereof, for the prevention and treatment of irritable bowel syndrome, comprising an intestinal motility modifier and alpha-D-galactosidase |
TNP2013000205A TN2013000205A1 (en) | 2011-11-15 | 2013-05-10 | ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF, FOR THE PREVENTION AND TREATMENT OF IRRITABLE BOWEL SYNDROME, COMPRISING AN INTESTINAL MOTILITY MODIFIER AND α-D-GALACTOSIDASE |
ZA2013/04157A ZA201304157B (en) | 2010-11-16 | 2013-06-06 | Orally administered pharmaceutical composition and preparation method thereof,for the prevention and treatment of irritable bowel syndrome,comprising an intestinal motility modifier and a-d-galactosidase |
MA36003A MA34730B1 (fr) | 2010-11-16 | 2013-06-10 | Composition pharmaceutique adaptée à l'administration par voie orale et son procédé de préparation avec un modificateur de la motilité intestinale et une a-d-galagtosidase, utilisation de ladite composition pharmaceutique pour la prévention et le traitement du syndrome de l'intestin irritable |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2010012480A MX2010012480A (es) | 2010-11-16 | 2010-11-16 | Composicion farmaceutica adaptada para administrarse oralmente y proceso para su preparación para su prevencion y tratamiento, del sindrome del intestino irritable, a base de un odificador dela motalidad intestinal y a-d- galactosidasa. |
MXMX/A/2010/012480 | 2010-11-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012067482A2 true WO2012067482A2 (es) | 2012-05-24 |
WO2012067482A3 WO2012067482A3 (es) | 2012-07-19 |
Family
ID=46084558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/MX2011/000139 WO2012067482A2 (es) | 2010-11-16 | 2011-11-15 | COMPOSICIÓN FARMACÉUTICA ADAPTADA PARA ADMINISTRARSE ORALMENTE Y PROCESO PARA SU PREPARACIÓN, PARA PREVENCIÓN Y TRATAMIENTO DEL SÍNDROME DE INTESTINO IRRITABLE, A BASE DE UN MODIFICADOR DE LA MOTILIDAD INTESTINAL Y α-D-GALAGTOSIDASA |
Country Status (21)
Country | Link |
---|---|
US (1) | US20150150953A1 (es) |
EP (1) | EP2641968A4 (es) |
JP (1) | JP2013542986A (es) |
KR (1) | KR20140037798A (es) |
CN (1) | CN103392000A (es) |
AR (1) | AR083889A1 (es) |
AU (1) | AU2011329917A1 (es) |
BR (1) | BR112013012102A2 (es) |
CA (1) | CA2818130A1 (es) |
CL (1) | CL2013001332A1 (es) |
CO (1) | CO6811847A2 (es) |
CR (1) | CR20130220A (es) |
DO (1) | DOP2013000109A (es) |
EC (1) | ECSP13012643A (es) |
MA (1) | MA34730B1 (es) |
MX (1) | MX2010012480A (es) |
PE (1) | PE20140379A1 (es) |
RU (1) | RU2013127273A (es) |
UY (1) | UY33732A (es) |
WO (1) | WO2012067482A2 (es) |
ZA (1) | ZA201304157B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2586280C1 (ru) * | 2015-04-23 | 2016-06-10 | Федеральное государственное бюджетное научное учреждение "Научный центр проблем здоровья семьи и репродукции человека" | Способ комплексной терапии функциональных нарушений пищеварения у детей дошкольного возраста |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103622936B (zh) * | 2013-12-09 | 2016-04-13 | 中国人民解放军广州军区武汉总医院 | 一种具有抗氧化功能的间苯三酚薄膜衣片及其制备方法 |
KR102440862B1 (ko) | 2020-02-24 | 2022-09-06 | 한림대학교 산학협력단 | 신규한 고정화 효소를 이용한 올리고당 감소 방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08512322A (ja) * | 1993-07-06 | 1996-12-24 | メルク エンド カンパニー インコーポレーテッド | H▲下2▼拮抗剤−胃腸運動性の薬剤組合せ物 |
US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US20040009234A1 (en) * | 2002-07-10 | 2004-01-15 | Meisel Gerard M. | Gastrointestinal compositions |
CO5790164A1 (es) * | 2006-08-10 | 2007-08-31 | Procaps S A | Composicion farmaceutica solida que incluye en combinacion un agente regulador de la motilidad intestinal y un agente antiflatulento |
-
2010
- 2010-11-16 MX MX2010012480A patent/MX2010012480A/es not_active Application Discontinuation
-
2011
- 2011-11-14 UY UY0001033732A patent/UY33732A/es not_active Application Discontinuation
- 2011-11-15 AU AU2011329917A patent/AU2011329917A1/en not_active Abandoned
- 2011-11-15 EP EP11841178.4A patent/EP2641968A4/en not_active Withdrawn
- 2011-11-15 KR KR1020137015555A patent/KR20140037798A/ko not_active Application Discontinuation
- 2011-11-15 CA CA2818130A patent/CA2818130A1/en not_active Abandoned
- 2011-11-15 CN CN2011800651365A patent/CN103392000A/zh active Pending
- 2011-11-15 WO PCT/MX2011/000139 patent/WO2012067482A2/es active Application Filing
- 2011-11-15 PE PE2013001061A patent/PE20140379A1/es not_active Application Discontinuation
- 2011-11-15 JP JP2013539789A patent/JP2013542986A/ja active Pending
- 2011-11-15 BR BR112013012102A patent/BR112013012102A2/pt not_active IP Right Cessation
- 2011-11-15 US US13/885,629 patent/US20150150953A1/en not_active Abandoned
- 2011-11-15 RU RU2013127273/15A patent/RU2013127273A/ru not_active Application Discontinuation
- 2011-11-16 AR ARP110104273A patent/AR083889A1/es not_active Application Discontinuation
-
2013
- 2013-05-14 CL CL2013001332A patent/CL2013001332A1/es unknown
- 2013-05-14 CR CR20130220A patent/CR20130220A/es unknown
- 2013-05-16 DO DO2013000109A patent/DOP2013000109A/es unknown
- 2013-05-27 EC ECSP13012643 patent/ECSP13012643A/es unknown
- 2013-06-06 ZA ZA2013/04157A patent/ZA201304157B/en unknown
- 2013-06-10 MA MA36003A patent/MA34730B1/fr unknown
- 2013-06-14 CO CO13143132A patent/CO6811847A2/es not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of EP2641968A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2586280C1 (ru) * | 2015-04-23 | 2016-06-10 | Федеральное государственное бюджетное научное учреждение "Научный центр проблем здоровья семьи и репродукции человека" | Способ комплексной терапии функциональных нарушений пищеварения у детей дошкольного возраста |
Also Published As
Publication number | Publication date |
---|---|
JP2013542986A (ja) | 2013-11-28 |
UY33732A (es) | 2012-06-29 |
CN103392000A (zh) | 2013-11-13 |
CO6811847A2 (es) | 2013-12-16 |
PE20140379A1 (es) | 2014-03-23 |
CA2818130A1 (en) | 2012-05-24 |
MA34730B1 (fr) | 2013-12-03 |
KR20140037798A (ko) | 2014-03-27 |
ZA201304157B (en) | 2016-01-27 |
WO2012067482A3 (es) | 2012-07-19 |
AU2011329917A1 (en) | 2013-06-06 |
CL2013001332A1 (es) | 2014-05-23 |
EP2641968A4 (en) | 2014-04-16 |
MX2010012480A (es) | 2012-05-16 |
EP2641968A2 (en) | 2013-09-25 |
ECSP13012643A (es) | 2013-10-31 |
US20150150953A1 (en) | 2015-06-04 |
AR083889A1 (es) | 2013-03-27 |
DOP2013000109A (es) | 2013-11-15 |
CR20130220A (es) | 2013-09-20 |
BR112013012102A2 (pt) | 2016-08-16 |
RU2013127273A (ru) | 2014-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6250100B2 (ja) | 腸運動調節剤、ガス滞留防止剤及び消化酵素を含む過敏性腸症候群の治療のための経口投与用医薬組成物及びその調製方法 | |
CN101516403B (zh) | 口腔崩解片及其制备方法 | |
JP4443119B2 (ja) | モダフィニルを含んで成る固体製剤 | |
CN101277721B (zh) | 口腔崩解片 | |
JP5864819B2 (ja) | 精神的障害、行動障害および認知障害の予防および治療のための医薬組成物 | |
CN106723087A (zh) | 一种含海带膳食纤维的片剂及其制备方法 | |
CA1207239A (en) | Gastrointestinal compositions | |
WO2012067482A2 (es) | COMPOSICIÓN FARMACÉUTICA ADAPTADA PARA ADMINISTRARSE ORALMENTE Y PROCESO PARA SU PREPARACIÓN, PARA PREVENCIÓN Y TRATAMIENTO DEL SÍNDROME DE INTESTINO IRRITABLE, A BASE DE UN MODIFICADOR DE LA MOTILIDAD INTESTINAL Y α-D-GALAGTOSIDASA | |
JP2005507397A (ja) | 速溶性の経口製剤 | |
CN105343056A (zh) | 一种治疗或预防肥胖型高血压的口服药物组合物及其用途 | |
CN102018721B (zh) | 一种碳酸钙二甲硅油咀嚼片及其制备方法 | |
CN101982174A (zh) | 一种镇咳平喘复方药物制剂的组方及其制备方法 | |
US8741344B1 (en) | Dispersible tablet | |
WO2021078110A1 (zh) | 预防或治疗肠易激综合征的药物组合 | |
OA16415A (en) | Orally administred pharmaceutical composition and preparation method thereof, for the prevention and treatment of irritable bowel syndrome, comprising an intestinal motility modifier and a-D-galactosidase. | |
JP5100634B2 (ja) | 口腔内速崩壊性錠剤 | |
JP2021187858A (ja) | 医薬製剤 | |
OA16412A (en) | Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof. | |
US20100272781A1 (en) | Sugar Free Chewable Tablets | |
CN101176732A (zh) | 一种盐酸氨基葡萄糖分散片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 001061-2013 Country of ref document: PE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013001332 Country of ref document: CL Ref document number: CR2013-000220 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 2818130 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2013539789 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011329917 Country of ref document: AU Date of ref document: 20111115 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201307589 Country of ref document: UA Ref document number: 13143132 Country of ref document: CO Ref document number: 2011841178 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013127273 Country of ref document: RU Kind code of ref document: A Ref document number: 20137015555 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13885629 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013012102 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013012102 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130515 |